Search Results
Dec 02, 2025, 05:00 ET vHive lanza una solución en tiempo real para validar instalaciones construidas para operadores de red móvil
construido. Los planes cambian, las condiciones in situ se modifican y los equipos instalan equipos utilizando información a menudo obsoleta. Con el 5G y el acceso inalámbrico fijo, que aumentan la necesidad de precisión, esta brecha persistente se ha convertido en un importante factor que contribuye
More news about: vHive
Dec 02, 2025, 03:00 ET Power Metallic Intercepts 4.40 Meters of 12.18% Cu (14.34% CuEqRec) included within 20.40 Meters of 2.91% Cu (3.58% CuEqRec) in Hole 25-029b at Lion, and Completes the Extension of PN-24-064 to define large off-hole BHEM anomaly
(g/t)( g/t )
More news about: Power Metallic Mines Inc.
Dec 02, 2025, 02:27 ET Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Extension1Poster presentation:David G. Vossler, MDSaturday, Dec 6
More news about: H. Lundbeck A/S
Dec 02, 2025, 02:25 ET Lundbeck to present comprehensive new bexicaserin dataset in patients with rare childhood-onset epilepsies, at American Epilepsy Society (AES) Annual Meeting
Extension1Poster presentation:David G. Vossler, MDSaturday, Dec 6
More news about: H. Lundbeck A/S
Dec 02, 2025, 00:00 ET GC Biopharma's Varicella Vaccine Strain 'MAV/06' Listed in WHO Position Paper
plasma derivatives and vaccines, and is expanding its global presence with successful US market entry of Alyglo® (intravenous immunoglobulin G) in 2024. In line with its mission to meet the demands of future healthcare, GC Biopharma continues to drive innovation by leveraging its core R&D
More news about: GC Biopharma
Dec 01, 2025, 23:30 ET Agora Powers Agnes AI to Launch Next-Generation AI Group Chat and Multi-Agent Collaboration System
https://www.youtube.com/watch?v=bS0G2ScKgjQAgnes AI: The AI-Native Office System Built for EveryoneAgnes AI is not a chatbot—it is a full AI-native
More news about: Agora, Inc.
Dec 01, 2025, 23:30 ET Agora Powers Agnes AI to Launch Next-Generation AI Group Chat and Multi-Agent Collaboration System
https://www.youtube.com/watch?v=bS0G2ScKgjQAgnes AI: The AI-Native Office System Built for EveryoneAgnes AI is not a chatbot—it is a full AI-native
More news about: Agora, Inc.
Dec 01, 2025, 21:00 ET NEXCOM Simplifies Time-Sensitive Networking for Industrial Edge
Network and Communication Solutions (NCS) unit, NEXCOM delivers cutting-edge platforms for Cybersecurity, OT Security, SD-WAN, SASE, Load Balancing, 5G uCPE, edge AI, and more. NCS specializes in professional design and manufacturing services, enabling reliable and scalable network infrastructures for
More news about: NEXCOM International Co., Ltd.
Dec 01, 2025, 21:00 ET NEXCOM Simplifies Time-Sensitive Networking for Industrial Edge
Network and Communication Solutions (NCS) unit, NEXCOM delivers cutting-edge platforms for Cybersecurity, OT Security, SD-WAN, SASE, Load Balancing, 5G uCPE, edge AI, and more. NCS specializes in professional design and manufacturing services, enabling reliable and scalable network infrastructures for
More news about: NEXCOM International Co., Ltd.
Dec 01, 2025, 17:58 ET Así se vivió la final de la Copa Odyssey con los monitores Odyssey OLED G9 y Odyssey G7
@Shuart9) protagonizaron un encuentro épico potenciado por la tecnología de los monitores Odyssey OLED G9 y Odyssey G7, donde la velocidad y la precisión marcaron la diferencia.
More news about: Samsung Mexico
Dec 01, 2025, 17:31 ET Colorectal Cancer Market Set to Expand Throughout Forecast Period (2025-2034) Driven by Increasing Screening Rates and Novel Drug Approvals | DelveInsight
use of molecular profiling (MSI-H, BRAF V600E, HER2, and KRAS G12C) enables more personalized and effective treatment strategies.Emerging Molecular Targets Driving Next-Gen TherapiesEmerging targets such as KRAS G12C, NTRK fusions, and PIK3CA mutations provide new opportunities
More news about: DelveInsight Business Research, LLP
Dec 01, 2025, 16:06 ET Genetic Research Pinpoints a Lethal Risk Linked to Adams-Oliver Syndrome
malformations.Using their new mouse models, the research team determined that the most severe disruptions occurred among mice with a gene variant called RBPJ E89G that specifically affected cells forming vascular tissue. These cells generated significantly less NOTCH1 signaling than normal.NOTCH1
More news about: Cincinnati Children's Hospital Medical Center
Dec 01, 2025, 14:31 ET Cosmo y Glenmark anuncian la autorización de comercialización de Winlevi®
- Cosmo y Glenmark anuncian la autorización de comercialización de Winlevi® (crema de clascoterona 10 mg/g) para el tratamiento del acné en 17 países de EuropaDUBLIN y MUMBAI, India, 1 de diciembre de 2025 /PRNewswire/
More news about: Glenmark Pharmaceuticals
Dec 01, 2025, 12:45 ET Pátio Higienópolis inicia campanha Compre-Ganhe para o Natal 2025
Compre-Ganhe, do Natal 2025. Com R$1.000,00 (um mil reais) em compras, os clientes ganham um panetone com recheio de brigadeiro Pati Piva, de 908g – a campanha é restrita a um panetone por CPF e é válida até 24 dezembro, ou enquanto durar o estoque. Para participar, os clientes devem cadastrar-se
More news about: Shopping Pátio Higienópolis
Dec 01, 2025, 12:07 ET OUTFRONT Names Twitter Veteran Stacy Minero as New Chief Marketing & Experience Officer
video and global conversation. Earlier in her career at Mindshare and Mediavest, she guided cross-platform campaigns for American Express, Coca-Cola, P&G, and Hershey, blending TV, digital, social, out-of-home, and experiential to build impactful brand moments. Minero brings a bold, modern vision for
More news about: OUTFRONT Media Inc.
Dec 01, 2025, 12:00 ET James Hardie Industries plc (JHX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
INDUSTRIES PLC (JHX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 23, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at
More news about: Law Offices of Howard G. Smith
Dec 01, 2025, 12:00 ET Avantor, Inc. (AVTR) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
AVANTOR, INC. (AVTR), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 29, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at
More news about: Law Offices of Howard G. Smith
Dec 01, 2025, 12:00 ET CarMax, Inc. (KMX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
A LOSS IN CARMAX, INC. (KMX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE JANUARY 2, 2026 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at
More news about: Law Offices of Howard G. Smith
Dec 01, 2025, 12:00 ET Marex Group PLC (MRX) Shareholders Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
LOSS IN MAREX GROUP PLC (MRX), CONTACT THE LAW OFFICES OF HOWARD G. SMITH BEFORE DECEMBER 8, 2025 (LEAD PLAINTIFF DEADLINE) TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at
More news about: Law Offices of Howard G. Smith
Dec 01, 2025, 12:00 ET Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome.As defined, CLS occurred in 27% of patients
More news about: Citius Oncology, Inc.
Dec 01, 2025, 10:00 ET Mixx Technologies 完成 3,300 萬美元 A 輪融資，透過全棧光整合技術重新定義人工智能基礎架構
Technologies——專注於為人工智能 (AI) 基礎架構提供高效能、系統級光學連接解決方案的創新企業——今日宣佈成功完成 3,300 萬美元的 A 輪融資。本輪融資由 ICM HPQC 基金領投，TDK Ventures、Systemiq Capital、Banpu Innovation & Ventures、G Vision Capital、Ajinomoto Group Ventures 以及其他戰略合作夥伴共同參與。這輪認購額超額的募資，彰顯投資者對 Mixx 突破性方法的高度信心。
More news about: Mixx Technologies, Inc
Dec 01, 2025, 10:00 ET Mixx Technologies Raises $33M Series-A to Redefine AI Infrastructure through Full-Stack Optical Integration
said Dr. Luke Tang, Managing Partner at G Vision Capital. "Mixx's photonic architecture unlocks inference throughput by removing the interconnect bottleneck and enabling fully disaggregated, high-utilization AI systems." Further, Stella Jin, Managing Partner at G Vision Capital, added, "We're excited to
More news about: Mixx Technologies, Inc
Dec 01, 2025, 10:00 ET Mixx Technologies Raises $33M Series-A to Redefine AI Infrastructure through Full-Stack Optical Integration
round. The financing was led by ICM HPQC Fund, with participation from TDK Ventures, Systemiq Capital, Banpu Innovation & Ventures, G Vision Capital, Ajinomoto Group Ventures, AVITIC Innovation Fund, and other strategic partners. The oversubscribed round reflects strong investor confidence
More news about: Mixx Technologies, Inc
Dec 01, 2025, 10:00 ET Mixx Technologies Raises $33M Series-A to Redefine AI Infrastructure through Full-Stack Optical Integration
Series A funding round. The financing was led by ICM HPQC Fund, with participation from TDK Ventures, Systemiq Capital, Banpu Innovation & Ventures, G Vision Capital, Ajinomoto Group Ventures, AVITIC Innovation Fund, and other strategic partners. The oversubscribed round reflects strong investor confidence
More news about: Mixx Technologies, Inc
Dec 01, 2025, 09:34 ET Cosmo and Glenmark Announce Market Authorisation of Winlevi® (clascoterone) 10 mg/g cream for Treatment of Acne in 17 countries in Europe
Pharmaceuticals Limited (Glenmark), announced that the European Commission (EC) has granted Marketing Authorization (MA) for Winlevi® (clascoterone 10 mg/g cream), following the positive opinion issued by the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) on August 25, 2025.
More news about: Glenmark Pharmaceuticals